Clinical Topics

Adjuvant Chemotherapy Improves Survival in Rectal Cancer

by U.S. Medicine

June 15, 2018

DURHAM, NC — The standard of care for locoregionally advanced rectal cancer (LARC) in the United States usually involves adjuvant chemotherapy (AC) following chemoradiation (CRT) and total mesorectal excision (TME).

The concern raised by a new study in the Journal of Clinical Oncology, however, is that data proving benefits have been lacking.1

Researchers from the Durham, NC, VAMC and Duke University Medical Center sought to remedy that, by examining the role, optimal regimen and duration of AC in the mandatory, prospectively collected cancer registry of the largest integrated health system in the United States.

To accomplish that, the study team used the VA Central Cancer Registry, including Stage II-III rectal cancer patients diagnosed between January 2001 and April 2011, if they received neoadjuvant CRT, followed by TME, with or without AC.

At least four months of therapy was defined as “adequate chemotherapy,” and survival outcomes were compared. Overall, 649 patients were identified, with 323 receiving AC, while 326 did not (OBS). For the mostly white and male group, mean age 63, median follow-up was 66 months. Almost half of the patients, 49.2% had Stage II disease.

Results indicated that median overall survival (OS) for all patients was 92 months, with six-year OS at 56.8%. Median OS was 72 months for the OBS group and not reached (NR) for the AC group (p < 0.001).

Six-year OS was 49.5% for OBS and 64.1% for AC (p < 0.0001). On PS matched analysis, OS was improved, favoring AC (p < 0.0001).

The researchers reported that median disease-specific survival (DSS) was NR for the whole group and NR for the OBS and AC groups. At six years, DSS was 73.6% for the whole group and 67.9% for OBS vs. 79.2% for AC (p < 0.001). The study team concluded that PS matched analysis for DSS favored AC (p = 0.0004).

No significant difference was detected in OS (p = 0.554) or DSS (p = 0.680) when comparing single vs. multiagent chemotherapy and no significant difference in OS (p = 0.766) or DSS (p = 0.271) when comparing adequate vs. inadequate chemotherapy.

“In this VA population of LARC patients treated with neoadjuvant CRT followed by TME, the addition of AC was found to improve both OS and DSS compared to OBS,” the study authors concluded. “There was no improvement in OS or DSS with the addition of a multi-agent over single-agent chemotherapy.”


1Spiegel D, Boyer M, Hong JC, Williams CD, e. al. Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis. Journal of Clinical Oncology 2018 36:4_suppl, 741-741.

Comments are closed here.


Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up